Prescription drug · ANDA
Fluoxetine NDC 67046-1670
Fluoxetine hydrochloride 20 mg/1 · Capsule · Oral · Coupler LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 67046-1670-3 | 67046167003 | 30 CAPSULE in 1 BLISTER PACK (67046-1670-3)Marketed from Apr 22, 2026 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Fluoxetine
- Generic name (nonproprietary)
- fluoxetine
- Active ingredients
- Fluoxetine hydrochloride — 20 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- Coupler LLC
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 206993
- Marketing start
- Listing expires
- Other FDA classes
- Serotonin Uptake Inhibitors (Mechanism)
- Identifiers
- Product ID 67046-1670_501184f6-feb7-63d0-e063-6394a90a84c8SPL ID 501184f6-feb7-63d0-e063-6394a90a84c8SPL set ID 50117d4f-0777-54d3-e063-6394a90a857cRxCUI 310385UNII I9W7N6B1KJ
- Pharmacologic class
- Serotonin Reuptake Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N467046167003followed by a unit qualifier and the quantityPackage 67046-1670-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
Fluoxetine capsules are indicated for the treatment of: • Acute and maintenance treatment of Major Depressive Disorder [ see Clinical Studies (14.1)]. • Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [ see Clinical Studies (14.2 )]. • Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa [ see Clinical Studies (14.3 )]. • Acute treatment of Panic Disorder, with or without agoraphobia [ see Clinical Studies (14.4 ) ]. Fluoxetine capsules and Olanzapine in Combination is indicated for the treatment of: • Acute treatment of depressive episodes associated with …
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 206993
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Fluoxetine | Fluoxetine hydrochloride 10 mg/1 | CapsuleOral | PD-Rx Pharmaceuticals, Inc. | 72789-557 |
| Fluoxetine | Fluoxetine hydrochloride 10 mg/1 | CapsuleOral | Modavar Pharmaceuticals LLC | 72241-007 |
| Fluoxetine | Fluoxetine hydrochloride 20 mg/1 | CapsuleOral | Modavar Pharmaceuticals LLC | 72241-008 |
| Fluoxetine | Fluoxetine hydrochloride 40 mg/1 | CapsuleOral | Modavar Pharmaceuticals LLC | 72241-009 |
| Fluoxetine | Fluoxetine hydrochloride 20 mg/1 | CapsuleOral | Cadila Pharmaceuticals Limited | 71209-041 |
| Fluoxetine | Fluoxetine hydrochloride 10 mg/1 | CapsuleOral | Cadila Pharmaceuticals Limited | 71209-040 |
| Fluoxetine | Fluoxetine hydrochloride 40 mg/1 | CapsuleOral | Cadila Pharmaceuticals Limited | 71209-042 |